Pharmaceuticals & Biotechnology Sector Weekly (2026-09-29)

Report date: 2026-09-29 | Data cutoff: US close 2026-09-28; HK/A-share close 2026-09-29 Sources: grok-x x_search live retrieval of X posts (trailing 168 hours from 2026-09-22; industry-signal window extended to 2026-09-15). All prices and percentage moves are pulled live from the eastmoney quote service — never taken from the text of X posts. Supplementary fact-checking via public CNBC/Reuters reporting. For informational and educational purposes only. Not investment advice.

1. Key Events

1. Kodiak Sciences' two eye-disease candidates matched Eylea in Phase 3 — the single biggest event of the week. @FierceBiotech: "Two of Kodiak Sciences' drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year." @endpts adds: "with fewer injections. An FDA filing is coming in the fourth quarter." Verified pricing: KOD closed 9/28 at $89.92, +177.96%, on $3.22bn of turnover. 𝕏¹ 𝕏²

2. The other side of the trade: Regeneron (REGN), the Eylea originator, closed 9/28 at $752.25, down 4.54% — the sharpest decline among large-cap pharma this week, as the long-acting wet-AMD competitive landscape was repriced. (Same event source; price from live eastmoney quote.)

3. InnoCare and Eli Lilly signed a collaboration worth up to $3.35bn. @Reuters: "China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion" (9/24). Verified pricing: InnoCare HK (09969.HK) closed 9/29 at HK$14.38, +1.99%; A-share (688428.SH) at RMB 28.88, +0.87%; LLY closed 9/28 at $1,184.78, +0.11%. 𝕏

4. Merck and Daiichi Sankyo withdrew the FDA filing for their B7-H3 ADC (ifinatamab deruxtecan) in small cell lung cancer. @endpts: "Merck and Daiichi pulled their FDA filing for a B7-H3 ADC in small cell lung cancer. It's the second withdrawal from their $4B ADC pact." @FierceBiotech notes the FDA said they lacked data for accelerated approval. MRK closed 9/28 at $148.69, -0.06%. 𝕏¹ 𝕏²

5. Novo Nordisk licensed Swedish microcap Nanexa's PharmaShell long-acting injectable platform for up to $1.33bn (€1.17bn). @CNBC: "Pharma stock soars 150% on injectables deal with Wegovy maker Novo." Per CNBC, Nanexa opened up more than 150% in Stockholm (this microcap is outside our quote coverage — not verified against an exchange snapshot). Novo's ADR (NVO) closed 9/28 at $38.71, -0.23%. 𝕏

6. Primary-market thaw: City Therapeutics filed for an IPO; AdaRx raised $446.3mn in an upsized IPO. @business (Bloomberg): "Adarx Pharmaceuticals, a late-stage developer of gene therapies, raised $446.3 million in an upsized IPO that priced at the top of its marketed range," and reported a ~30% first-day gain (newly listed; no eastmoney snapshot available — not verified against an exchange snapshot). 𝕏¹ 𝕏²

7. China expanded export controls on drug precursor chemicals. @zerohedge: "China Expands Export Controls On Drug Precursor Chemicals Ahead Of Trump-Xi Talks" (9/24) — the highest-engagement pharma-related media post of the week. 𝕏

8. Novo Nordisk's CEO signalled M&A to strengthen the pipeline. @CNBC: "Novo CEO signals M&A opportunities to strengthen drug pipeline" (9/22). 𝕏

2. Institutional & Media Coverage

Factual reporting

• Ophthalmology reshuffle (@FierceBiotech / @endpts): Both trade outlets covered Kodiak's Phase 3 on the same day with consistent framing — comparable efficacy to Eylea with fewer injections, with an FDA filing planned for Q4. FierceBiotech headlined it "Kodiak roars back," stressing this was a previously written-off asset that has been resurrected. Engagement: @FierceBiotech ≈40 likes; @endpts ≈2 likes. 𝕏¹ 𝕏²

• Merck/Daiichi second ADC withdrawal (@endpts / @FierceBiotech): Both note this is the second withdrawal under the $4bn ADC pact, with the direct cause being FDA feedback that the accelerated-approval data package was insufficient. 𝕏¹ 𝕏²

• Mirum hits Phase 3 primary endpoint in chronic hepatitis delta (@FierceBiotech): "A phase 3 trial of Mirum Pharmaceuticals' chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech's efforts to enter a space recently colonized by Gilead Sciences." Verified pricing: MIRM closed 9/28 at $87.96, -1.94% (positive data, but the stock closed lower on the day); Gilead (GILD) closed at $152.21, +0.85%. 𝕏

• Otsuka/Ionis ALS candidate hits Phase 3 primary endpoint (@FierceBiotech, 9/22): "positioning the partners to talk to regulators about expedited approvals." IONS closed 9/28 at $45.57, +2.40%. 𝕏

• Roche kidney drug hits Phase 3 goal (@endpts, 9/23): "Roche's kidney drug hit its Phase 3 goal, setting up a bid for accelerated approval in a crowded market." Roche ADR (RHHBY) closed 9/28 at $53.37, -1.98%. 𝕏

• Kyverna CAR-T long-term data in stiff person syndrome (@endpts, 9/24): "Kyverna's CAR-T improved mobility by a median 49% at one year in patients with stiff person syndrome, data it plans to take to the FDA by the end of this year." KYTX closed 9/28 at $6.82, +0.15%. 𝕏

• Primary market (@business / Bloomberg): City Therapeutics filed to IPO — "as it looks to secure more funding for drugs that treat disease by silencing disease-related proteins" (RNAi, Fidelity-backed); AdaRx upsized and priced at the top of its range for $446.3mn. Both posts ranked among the highest-viewed pharma media posts this week (City Therapeutics ≈30k views). 𝕏¹ 𝕏² 𝕏³

• Policy / supply chain (@zerohedge, 9/24): China expanded export controls on drug precursor chemicals ahead of the Trump-Xi talks. ≈109 likes, 28 reposts, 87k views — the most-engaged pharma-adjacent media post of the week, a sign that politicisation of the API supply chain is drawing rising attention.

Views / ratings

Within this week's retrieval window, the newswire and institutional whitelist accounts (@DeItaone, @unusual_whales, @firstsquawk, @FactSet, @TheTranscript_, etc.) produced no rating changes or price-target revisions on pharma names; the @CNBC piece on Novo's CEO is a paraphrase of management, not third-party research. This section is therefore intentionally brief.

3. KOL Bull & Bear Views

Note: this week the biotech KOL whitelist (@bradloncar / @ldtimmerman / @JohnCendpts) posted mainly industry news and interviews; no explicitly bearish or cautious posts were retrieved from them. The bear case came from a long-tail buy-side account found in the broad search. Engagement figures are as returned by the search.

Bullish

• @bradloncar (Brad Loncar): congratulated the City Therapeutics IPO filing — "Congrats @JMaraganore and Andy Orth on the City Therapeutics IPO filing. 🎉" RNAi veteran Maraganore (ex-Alnylam CEO) returning to the public market is read as a marker of primary-market sentiment repair. ≈57 likes / 9.9k views. 𝕏

• @bradloncar: "I was impressed by MDG's cool signature on today's European pharma letter." — a positive read on the European pharma industry's joint letter and the underlying policy fight. ≈18 likes / 3.1k views. 𝕏

• @stageanalysis (technical KOL): "Biotechnology industry group leading currently with a further Stage 2 continuation breakout to new highs," listing the strongest names as MRNA, NTRA, GMAB, TWST, HALO, GILD, KYMR, BIIB, EXEL, REGN, ARGX, ABBV. ≈19 likes / 2 reposts / 3.96k views. (Posted 9/23; note REGN — one of its picks — fell 4.54% on 9/28 on the Kodiak data, so the technical leadership list was interrupted by a fundamental event.) 𝕏

• @OMillionaires: "Innovation Is Driving a New Bull Market in Biotech. … $XBI has risen 28%, more than twice the gain of the S&P 500," naming $MRNA $MRK $RVMD $BMY $SMMT. ≈2 likes / 4.7k views (the percentage figures are the author's own and are not verified here; XBI closed 9/28 at $156.61, +1.02% on the day). 𝕏

• @10xthinker: a three-part bull case — "1) Big Pharma patent cliff 2) AI in drug discovery … Best approach is to have basket approach via ETFs - $IBB … $XBI." Very low engagement (0 likes / 113 views); included only as a sentiment sample. IBB closed 9/28 at $210.71, +0.45%. 𝕏

• @ldtimmerman (Luke Timmerman): teased a podcast with Spyre Therapeutics CEO Cameron Turtle on "Long-lasting antibodies for immune disorders" — long-acting autoimmune biologics remain his focus. ≈9 likes / 1.2k views. 𝕏

Bearish

• @buysidebio (buy-side view): the most substantive cautious take of the week, on four counts — "Biotech headwinds: median co worth $403M … 10Y 5.11% … recent M&A disappointing. MRNA = 64% of the net gain since Aug 5 while the median stock is -5%." The core argument: index gains are concentrated in a handful of names while the median stock is still falling, and elevated long-end yields continue to compress small-cap biotech valuations. ≈14 likes / 1 repost / 2.16k views. (The 10Y yield and median-market-cap figures are the author's own and were not independently verified; Moderna closed 9/28 at $197.28, -0.80%.) 𝕏

• Catalyst-calendar account @BiopharmIQ also flagged tail risk: its 9/28 pre-open "red" list included $MRK (ifinatamab deruxtecan withdrawal), $MIRM and $ACET. Verified: ACET closed 9/28 at $6.35, -29.60%. 𝕏

• China assets: no substantive bull/bear discussion was retrieved on X this week for BeiGene, WuXi AppTec, Hengrui or Innovent (neither English nor Chinese keywords returned results). Not padded.

4. Buzz & Sentiment Shifts

US biotech (XBI / IBB): attention shifted decisively from sector narrative to single-event trading. Early in the week (9/23) the dominant thread was a technical breakout and a "new biotech bull market"; by Monday 9/28 that was entirely overwritten by Kodiak's Phase 3 — KOD traded $3.22bn of volume against a $5.65bn closing market cap, an extreme turnover ratio. On balance, explicitly bullish posts outnumbered bearish ones by roughly 3–4x, but the bull case was mostly ETF/technical generalities while the bear case (@buysidebio) offered falsifiable data (median stock -5%, gains concentrated in MRNA). That combination — loud sentiment, divergent fundamentals — is the week's most notable structural feature.

Large-cap pharma (LLY / MRK / NVO / PFE / ABBV): low discussion volume and neutral tone. On 9/28 closes: LLY +0.11%, MRK -0.06%, NVO -0.23%, PFE +0.17%, ABBV +0.73% — all within ±1%. In other words, this week's industry news flow (ADC withdrawal, Nanexa licensing, InnoCare deal) had almost no marginal pricing impact on mega-caps; the market's attention was on binary events in small caps.

Ophthalmology / wet AMD: from near-zero discussion last week to the highest-buzz sub-theme in the sector, and with a cleanly paired long/short stance — strongly bullish Kodiak, turning bearish Regeneron (KOD +177.96% vs REGN -4.54%). It was the only theme this week where the stated positioning was simultaneously confirmed by price action.

China pharma assets: X-platform buzz was effectively nil, surfacing only indirectly via @Reuters' coverage of the InnoCare–Lilly deal. InnoCare's HK and A-shares did respond on 9/29 (+1.99% / +0.87%), but overseas social sentiment produced no follow-through discussion at all — cross-market information transmission remains asymmetric, which is itself an observable data point.

5. First-hand Industry Signals (Last 14 Days)

Interpretation of the key events

① Kodiak vs. Regeneron: repricing long-acting wet AMD. Kodiak's result is not about superior efficacy — it is about comparable efficacy with fewer injections. The core pain point in ophthalmic anti-VEGF is intravitreal injection burden, so non-inferiority plus reduced dosing is itself the differentiator. The tape delivered a textbook symmetric reaction: KOD +177.96% (market cap to $5.65bn) against REGN -4.54% (closing $752.25, market cap $77.4bn). Two caveats: first, KOD's TTM P/E is -21.46 — the company is still loss-making, so the 178% move is entirely a repricing of future cash flows and carries very high risk; second, "Q4 filing" is a plan, and between filing, approval, and actually displacing Eylea's prescription share sit a full review cycle and physician prescribing inertia. Regeneron's 4.5% decline looks like a one-off discount for higher long-term competitive intensity, not a cut to near-term revenue.

② Merck/Daiichi's second ADC withdrawal: the accelerated-approval window for ADCs is narrowing. This is the second withdrawal under the $4bn pact, and the stated reason is explicitly insufficient data for accelerated approval. For several years ADCs have travelled a relatively smooth path to accelerated approval on single-arm trials and ORR endpoints; the FDA's clear pushback here is negative for the sector's valuation assumptions, because it raises the implied cost and time from data to market. For Merck itself, a -0.06% move on a $148.69 close says the market had long since stopped crediting this asset with near-term contribution. But for small- and mid-cap biotechs whose entire narrative rests on ADCs — including the many Chinese biotechs out-licensing ADC assets to multinationals — this is a regulatory signal that warrants recalibration.

③ InnoCare–Lilly ($3.35bn) and Novo–Nanexa ($1.33bn): multinationals keep accelerating external innovation sourcing. Two deals in the same week point the same direction: large pharma is no longer building early-stage capability in house, but buying platforms and assets with upfronts plus milestones. Novo's ~$700mn upfront to Nanexa is more than half the headline value — an unusually high upfront ratio that reflects strategic urgency around long-acting injectable formulation. This is the same logic line as @CNBC's report that Novo's CEO is signalling M&A. For Chinese biotech, the Lilly deal again validates out-licensing as the primary monetisation path. Worth flagging, though: InnoCare's HK and A-shares reacted modestly (+1.99% / +0.87%), which suggests the market already heavily discounts "up to $X billion" headlines laden with contingent milestones — headline value is not contracted cash flow.

This report is compiled from public information and live social-platform retrieval. Third-party views quoted here do not represent the platform's position. All prices and percentage moves come from market data feeds; anything not marked "Confirmed" should be treated as rumour or expectation. For informational and educational purposes only. It is not a recommendation to buy or sell any security and does not take into account any individual investor's financial situation or objectives. Markets carry risk; invest with caution.